Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pascal Vranckx

Showing results (101-110 of 305) with videos related to

Pageof 31
Sort By:
Journal of the American College of Cardiology|February 18, 2014
4-year clinical outcomes and predictors of repeat revascularization in patients treated with new-generation drug-eluting stents: a report from the RESOLUTE All-Comers trial (A Randomized Comparison of a Zotarolimus-Eluting Stent With an Everolimus-Eluting Stent for Percutaneous Coronary Intervention)Masanori Taniwaki, Giulio G Stefanini, Sigmund Silber, et al.
Catheterization and Cardiovascular Interventions : Official Journal of the Society for Cardiac Angiography & Interventions|April 11, 2009
Assisted circulation using the TandemHeart during very high-risk PCI of the unprotected left main coronary artery in patients declined for CABGPascal Vranckx, Carl Johann Schultz, Marco Valgimigli, et al.
Clinical Research in Cardiology : Official Journal of the German Cardiac Society|October 24, 2020
Clinical risk predictors in atrial fibrillation patients following successful coronary stenting: ENTRUST-AF PCI sub-analysisAndreas Goette, Lars Eckardt, Marco Valgimigli, et al.
Journal of Cardiovascular Medicine (Hagerstown, Md.)|May 29, 2024
Edoxaban and/or colchicine for patients with coronavirus disease 2019 managed in the out-of-hospital setting (CONVINCE): a randomized clinical trialAntonio Landi, Nuccia Morici, Pascal Vranckx, et al.
Eurointervention : Journal of Europcr in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology|February 18, 2014
Clinical outcome of patients with stable ischaemic heart disease as compared to those with acute coronary syndromes after percutaneous coronary interventionPascal Vranckx, Bindu Kalesan, Giulio G Stefanini, et al.
American Heart Journal|February 9, 2018
Evaluation of the safety and efficacy of an edoxaban-based antithrombotic regimen in patients with atrial fibrillation following successful percutaneous coronary intervention (PCI) with stent placement: Rationale and design of the ENTRUST-AF PCI trialPascal Vranckx, Thorsten Lewalter, Marco Valgimigli, et al.
European Heart Journal. Cardiovascular Pharmacotherapy|November 25, 2022
Dual antiplatelet therapy duration after percutaneous coronary intervention in patients with indication to oral anticoagulant therapy. A systematic review and meta-analysis of randomized controlled trialsClaudio Montalto, Francesco Costa, Sergio Leonardi, et al.
The American Journal of Cardiology|February 15, 2003
Usefulness of percutaneous left ventricular assistance to support high-risk percutaneous coronary interventionsPedro A Lemos, Paul Cummins, Chi-hang Lee, et al.
JACC. Cardiovascular Interventions|December 17, 2013
Two-year outcomes after first- or second-generation drug-eluting or bare-metal stent implantation in all-comer patients undergoing percutaneous coronary intervention: a pre-specified analysis from the PRODIGY study (PROlonging Dual Antiplatelet Treatment After Grading stent-induced Intimal hyperplasia studY)Marco Valgimigli, Matteo Tebaldi, Marco Borghesi, et al.
Eurointervention : Journal of Europcr in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology|November 26, 2015
Long-term ticagrelor monotherapy versus standard dual antiplatelet therapy followed by aspirin monotherapy in patients undergoing biolimus-eluting stent implantation: rationale and design of the GLOBAL LEADERS trialPascal Vranckx, Marco Valgimigli, Stephan Windecker, et al.
Pageof 31

Showing results (101-110 of 305) with videos related to

Sort By:
Pageof 31
Journal of the American College of Cardiology|February 18, 2014
4-year clinical outcomes and predictors of repeat revascularization in patients treated with new-generation drug-eluting stents: a report from the RESOLUTE All-Comers trial (A Randomized Comparison of a Zotarolimus-Eluting Stent With an Everolimus-Eluting Stent for Percutaneous Coronary Intervention)Masanori Taniwaki, Giulio G Stefanini, Sigmund Silber, et al.
Catheterization and Cardiovascular Interventions : Official Journal of the Society for Cardiac Angiography & Interventions|April 11, 2009
Assisted circulation using the TandemHeart during very high-risk PCI of the unprotected left main coronary artery in patients declined for CABGPascal Vranckx, Carl Johann Schultz, Marco Valgimigli, et al.
Clinical Research in Cardiology : Official Journal of the German Cardiac Society|October 24, 2020
Clinical risk predictors in atrial fibrillation patients following successful coronary stenting: ENTRUST-AF PCI sub-analysisAndreas Goette, Lars Eckardt, Marco Valgimigli, et al.
Journal of Cardiovascular Medicine (Hagerstown, Md.)|May 29, 2024
Edoxaban and/or colchicine for patients with coronavirus disease 2019 managed in the out-of-hospital setting (CONVINCE): a randomized clinical trialAntonio Landi, Nuccia Morici, Pascal Vranckx, et al.
Eurointervention : Journal of Europcr in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology|February 18, 2014
Clinical outcome of patients with stable ischaemic heart disease as compared to those with acute coronary syndromes after percutaneous coronary interventionPascal Vranckx, Bindu Kalesan, Giulio G Stefanini, et al.
American Heart Journal|February 9, 2018
Evaluation of the safety and efficacy of an edoxaban-based antithrombotic regimen in patients with atrial fibrillation following successful percutaneous coronary intervention (PCI) with stent placement: Rationale and design of the ENTRUST-AF PCI trialPascal Vranckx, Thorsten Lewalter, Marco Valgimigli, et al.
European Heart Journal. Cardiovascular Pharmacotherapy|November 25, 2022
Dual antiplatelet therapy duration after percutaneous coronary intervention in patients with indication to oral anticoagulant therapy. A systematic review and meta-analysis of randomized controlled trialsClaudio Montalto, Francesco Costa, Sergio Leonardi, et al.
The American Journal of Cardiology|February 15, 2003
Usefulness of percutaneous left ventricular assistance to support high-risk percutaneous coronary interventionsPedro A Lemos, Paul Cummins, Chi-hang Lee, et al.
JACC. Cardiovascular Interventions|December 17, 2013
Two-year outcomes after first- or second-generation drug-eluting or bare-metal stent implantation in all-comer patients undergoing percutaneous coronary intervention: a pre-specified analysis from the PRODIGY study (PROlonging Dual Antiplatelet Treatment After Grading stent-induced Intimal hyperplasia studY)Marco Valgimigli, Matteo Tebaldi, Marco Borghesi, et al.
Eurointervention : Journal of Europcr in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology|November 26, 2015
Long-term ticagrelor monotherapy versus standard dual antiplatelet therapy followed by aspirin monotherapy in patients undergoing biolimus-eluting stent implantation: rationale and design of the GLOBAL LEADERS trialPascal Vranckx, Marco Valgimigli, Stephan Windecker, et al.
Pageof 31